Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.42 |
| ▸ | IGF1R | P08069 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.39 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.39 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.39 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | HPGDS | O60760 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11964274 | 0.88 | KDR (0.45) | EGFREPHX2HRH4PIK3C3TBK1 | |
| SCHEMBL11964247 | 0.86 | KMT2A (0.47) | IGF1RHRH4METAP1POLBAURKA | |
| SCHEMBL11964265 | 0.85 | AURKA (0.46) | EGFRHRH4PIK3C3TBK1AURKA | |
| SCHEMBL11964271 | 0.84 | PAK4 (0.46) | EGFRHRH4POLBAURKAFLT3 | |
| SCHEMBL11964251 | 0.84 | FLT3 (0.56) | EGFREPHX2HRH4PIK3C3TBK1 | |
| SCHEMBL11964281 | 0.84 | KDR (0.46) | EGFREPHX2AURKAFLT3 | |
| SCHEMBL16900378 | 0.84 | HRH4 (0.47) | EGFRHRH4AURKAMAPTMAPK1 | |
| SCHEMBL11964536 | 0.84 | SCN9A (0.47) | EGFREPHX2HRH4AURKAFLT3 | |
| SCHEMBL11952800 | 0.83 | EGFR (0.41) | EGFRIGF1REPHX2HRH4PIK3C3 | |
| SCHEMBL16900379 | 0.82 | HRH4 (0.43) | EGFRHRH4PIK3C3TBK1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9078902-B2 | Triazine derivatives and their therapeutical applications | NANTBIOSCIENCE, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-20120196860-A1 | Triazine derivatives and their therapeutical applications | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196860-A1 | Triazine derivatives and their therapeutical applications | MAP3K2, MAP3K5, MAP4K2 | EGFR 1106/4885IGF1R 1230/4885EPHX2 3795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.